Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer gets worldwide rights to GlycoMimetics lead compound GMI1070

Executive Summary

Glycobiology specialist GlycoMimetics Inc. (creating small molecules with similar structures and activities to those of bioactive carbohydrates) has licensed Pfizer Inc. exclusive global rights to its Phase II E-, P-, and L-selectin antagonist GMI1070 for vaso-occlusive crisis associated with sickle cell disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies